Dubois, Bruno, Zaim, Mohammed, Touchon, Jacques, Vellas, Bruno, Robert, Philippe, Murphy, Michael F., Pujadas-Navinés, Francesc, Rainer, Michael, Soininen, Hilkka, Riordan, Henry J., Kanony-Truc, Claire

New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]

Li, Wei, Zhao, Jian-Hua, Sun, Sheng-Gang, Zhang, Jie-Wen, Suo, Ai-Qin, Ma, Ming-Ming

Objective: To study the effects of memantine on cognitive and motor impairment in patients with Parkinson’s disease (PD).; Methods: A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control […]

Senanarong, Vorapun, Poungvarin, Niphon, Phanthumchinda, Kammant, Thavichachart, Nuntika, Chankrachang, Siwaporn, Praditsuwan, Rungnirund, Nidhinandana, Samart

The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state […]

Dombrovski, Alexandre Y., Mulsant, Benoit H., Ferrell, Robert E., Lotrich, Francis E., Rosen, Jules I., Wallace, Meredith, Houck, Patricia R., Mazumdar, Sati, Pollock, Bruce G.

The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]

Black, Ronald S., Sperling, Reisa A., Safirstein, Beth, Motter, Ruth N., Pallay, Allan, Nichols, Alice, Grundman, Michael

The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5 mg/kg or placebo (6 active, 2 placebo for 0.5 […]

Silver, Jonathan M., Koumaras, Barbara, Meng, Xiangyi, Potkin, Steven G., Reyes, Patricio F., Harvey, Philip D., Katz, Douglas I., Gunay, Ibrahim, Arciniegas, David B.

Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]

Rolland, Yves, Andrieu, Sandrine, Crochard, Anne, Goni, Sylvia, Hein, Christophe, Vellas, Bruno

Objectives: To quantify transitions of residents into or out of nursing homes (NHs) and to describe psychotropic drug prescription at admission and discharge and with regard to dementia diagnosis.; Design: A descriptive, cross-sectional, noninterventional study.; Setting: The setting included 300 NH in France.; Participants: Participants included 2231 NH residents.; Measurements: Participants reported the number, origin, […]

Kanagaratnam, Lukshe, Mahmoudi, Rachid, Novella, Jean-Luc, Jolly, Damien, Dramé, Moustapha, Trenque, Thierry

Introduction: Drug prescriptions represent an actionable item in the prevention of adverse drug reactions (ADRs). The aims of this study were to identify risk factors for the occurrence of ADRs, and to describe symptoms and drug interactions. Methods: This was a longitudinal study over a period of 19 months in an acute geriatric ward specializing […]